208 related articles for article (PubMed ID: 34326137)
1. Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.
Lu T; Ma R; Li Z; Mansour AG; Teng KY; Chen L; Zhang J; Barr T; Caligiuri MA; Yu J
Cancer Immunol Res; 2021 Oct; 9(10):1229-1241. PubMed ID: 34326137
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis.
Cho FN; Chang TH; Shu CW; Ko MC; Liao SK; Wu KH; Yu MS; Lin SJ; Hong YC; Chen CH; Hung CH; Chang YH
PLoS One; 2014; 9(10):e109352. PubMed ID: 25313995
[TBL] [Abstract][Full Text] [Related]
3. Engineering Receptor Expression on Natural Killer Cells Through Trogocytosis.
Somanchi A; Lee DA; Somanchi SS
Methods Mol Biol; 2016; 1441():253-65. PubMed ID: 27177672
[TBL] [Abstract][Full Text] [Related]
4. Trogocytosis-based generation of suppressive NK cells.
Caumartin J; Favier B; Daouya M; Guillard C; Moreau P; Carosella ED; LeMaoult J
EMBO J; 2007 Mar; 26(5):1423-33. PubMed ID: 17318190
[TBL] [Abstract][Full Text] [Related]
5. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.
Somanchi SS; Somanchi A; Cooper LJ; Lee DA
Blood; 2012 May; 119(22):5164-72. PubMed ID: 22498742
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
7. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.
Li Y; Basar R; Wang G; Liu E; Moyes JS; Li L; Kerbauy LN; Uprety N; Fathi M; Rezvan A; Banerjee PP; Muniz-Feliciano L; Laskowski TJ; Ensley E; Daher M; Shanley M; Mendt M; Acharya S; Liu B; Biederstädt A; Rafei H; Guo X; Melo Garcia L; Lin P; Ang S; Marin D; Chen K; Bover L; Champlin RE; Varadarajan N; Shpall EJ; Rezvani K
Nat Med; 2022 Oct; 28(10):2133-2144. PubMed ID: 36175679
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
9. Outsmarting trogocytosis to boost CAR NK/T cell therapy.
Ramezani F; Panahi Meymandi AR; Akbari B; Tamtaji OR; Mirzaei H; Brown CE; Mirzaei HR
Mol Cancer; 2023 Nov; 22(1):183. PubMed ID: 37974170
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases.
Caraux A; Lu Q; Fernandez N; Riou S; Di Santo JP; Raulet DH; Lemke G; Roth C
Nat Immunol; 2006 Jul; 7(7):747-54. PubMed ID: 16751775
[TBL] [Abstract][Full Text] [Related]
11. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
12. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
14. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
15. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
16. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
Shah N; Martin-Antonio B; Yang H; Ku S; Lee DA; Cooper LJ; Decker WK; Li S; Robinson SN; Sekine T; Parmar S; Gribben J; Wang M; Rezvani K; Yvon E; Najjar A; Burks J; Kaur I; Champlin RE; Bollard CM; Shpall EJ
PLoS One; 2013; 8(10):e76781. PubMed ID: 24204673
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
[TBL] [Abstract][Full Text] [Related]
18. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]